Colm McCauley, DO
Family Medicine · Cushing, OKNPI 1518980531
Payments from drug & device makers
Across 297 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Astellas Pharma US Inc$539
- AbbVie$489
- GSK$453
- Lilly USA, LLC$439
- Novo Nordisk$277
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,944100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $1,236 |
| Astellas Pharma US Inc | 23 | $539 |
| AbbVie(2 entities) | 45 | $489 |
| GSK | 25 | $453 |
| Lilly USA, LLC | 29 | $439 |
| Novo Nordisk | 20 | $277 |
| Boehringer Ingelheim | 17 | $248 |
| Pfizer | 18 | $239 |
| Exact Sciences | 7 | $151 |
| Mylan Specialty L.p. | 7 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $129 |
| Johnson & Johnson | 5 | $64 |
| Merck | 3 | $47 |
| Amgen | 2 | $44 |
| Antares Pharma, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Organon | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Novartis | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Indivior Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Corium, LLC | 1 | $11 |
How this compares
$4,959 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 94 | $103,564 |
| OzempicSemaglutide | 73 | $74,540 |
| EliquisApixaban | 74 | $59,655 |
| JardianceEmpagliflozin | 60 | $41,240 |
| XareltoRivaroxaban | 52 | $34,616 |
| VraylarCariprazine Hcl | 11 | $21,214 |
| TrulicityDulaglutide | 21 | $20,083 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $19,516 |
| FarxigaDapagliflozin Propanediol | 28 | $17,880 |
| JanuviaSitagliptin Phosphate | 25 | $13,684 |
| Spiriva RespimatTiotropium Bromide | 15 | $13,417 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,651 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 404 | $10,869 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,866 |
| OxycontinOxycodone Hcl | 13 | $8,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $439 | $123,647115 claims |
| Novo NordiskOzempic | $277 | $74,54073 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $248 | $62,83892 claims |
| PfizerEliquis | $239 | $59,65574 claims |
| Johnson & JohnsonXarelto, Invokana | $64 | $42,44665 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,236 | $37,17177 claims |
| AbbVieVraylar, Namzaric | $489 | $27,60222 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $453 | $23,08341 claims |
| MerckJanuvia, Janumet Xr | $47 | $19,88336 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $16 | $2,18412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Cushing
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.